Experts discussed the great advances and innovations they’ve seen this year in acute myeloid leukemia (AML) and multiple myeloma.

A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk ...

Multiple myeloma is a rare type of cancer. It starts with the uncontrolled production of plasma cells. These are a type of white blood cell in the bone marrow. Healthy plasma cells make antibodies ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Advances in multiple myeloma treatment this year were marked by the resurrection of a drug that had been previously ...

"This study provides strong evidence for the use of daratumumab as a treatment for high-risk smoldering multiple myeloma," says Dr. Rajkumar, the Edward W. and Betty Knight Scripps Professor of ...

The phase 3 AQUILA study showed a 63.1% progression-free rate at 5 years with daratumumab versus 40.8% with active monitoring ...

Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma ...

Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced a collaboration with Dr. C. Ola Landgren, MD, PhD, h ...